With Divestitures, Schering Gets OK To Buy Rival

Law360, New York (November 16, 2007, 12:00 AM EST) -- Schering-Plough Corp. received a thumbs up on its $14.4 billion takeover of an Akzo-Nobel NV unit on Friday, after it agreed to sell off certain assets in response to regulatory concerns that the deal could harm competition in the poultry vaccine market.

A day after the Federal Trade Commission lodged a complaint challenging Schering-Plough's bid to buy Akzo-Nobel's Organon BioSciences NV, the regulator announced that the pharmaceutical giant had agreed to divest the rights and assets it needs to develop and sell three types of poultry...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.